Medtronic Plc (MDT) experienced a dynamic third quarter in 2026. Investors showed mixed sentiments with firms like
Pekin Hardy Strauss Inc and
Comgest Global Investors S.A.S. selling their stakes, while
Advisors Capital Management LLC and
Vanguard Group Inc. increased their holdings. Although the stock experienced a dip post-earnings announcement, Medtronic outpaced expectations, reporting the
highest enterprise revenue growth in 10 quarters. Influenced by a surge in its
Cardiac Ablation and Diabetes Revenue, the firm notably surpassed Wall Street estimates for Q3 earnings. The company witnessed
record 10-Quarter revenue spike majorly driven by its
Cardiovascular and Robotics sectors. MDT stock managed to rise, backed by Q3 earnings, revenue beat but took a hit due to contracting margins. Medtronic also intends to acquire CathWorks, thereby advancing its
innovation strategy. The company received FDA clearance for the
Stealth AXiS™ surgical system, marking a milestone in the medical technique, furthermore raising optimism with its
Renal Denervation procedure volumes. The announcement of a
Fiscal 2026 Adjusted EPS Range of $5.62 to $5.66 reasserts commitment towards growth.
Medtronic Plc MDT News Analytics from Tue, 19 Aug 2025 07:00:00 GMT to Sat, 21 Feb 2026 15:13:34 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
